Federal Circuit Revisits Myriad Breast Cancer Gene Claims
WASHINGTON – It was an encore performance in the Federal Circuit Friday as the panel of judges that ruled on the Association for Molecular Pathology v. Myriad Genetics Inc. last year listened to pretty much the same arguments about the patentability of isolated DNA all over again.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST